Hannah’s Hope Fund 2012 UPDATE!
Hannah’s Hope Fund 2012 UPDATE! – Giant Axonal Neuropathy is a ravaging, neurodegenerative disorder that steals life in the second or third decade after rendering it’s victims quadriplegics, unable to speak or swallow. The mission of Hannah’s Hope Fund (HHF) is to raise funds for a treatment and cure of Giant Axonal Neuropathy (GAN). Lori and Matt Sames co-founded HHF following the diagnosis of their youngest daughter, Hannah, in March of 2008. At the time of Hannah’s diagnosis, Lori was only able to find one scientist in the world actively studying GAN, Dr. Pascale Bomont, in France. Now, the scientists working with Hannah’s Hope Fund have a GAN gene therapy Investigational New Drug (IND) that we are working to push to Phase 1 and Phase 2 clinical trials. However, once HHF is done paying for the FDA required safety studies, there is no money left to fund the human Phase 1 trial. Another miracle has occurred! Doris Buffett’s Sunshine Lady Foundation has given Hannah’s Hope Fund an “all-or-nothing” matching grant challenge. If you help us raise 0000 by April 30th, 2013, The Sunshine Lady Foundation will provide a 0000 matching grant. Please help us save precious and innocent lives being taken by GAN. Donate at: www.hannahshopefund.org and share this Youtube link with everyone you know. Families with GAN world-wide are eternally grateful for your support.
There's Nothing Fishy About Amarin
Filed under: drug treatment news 2013
At the least, they were looking for the biotech to find a partner to pay for the commercialization of the drug. … $ 100 million through non-equity financing while hiring 250 to 300 sales people for the expected commercial launch of Vascepa in the …
Read more on DailyFinance
Raptor Drug FDA Action Date Delayed
Filed under: drug treatment news 2013
The FDA's final decision is now expected by April 30, 2013 instead of January 30, 2013. Raptor Pharma is looking to get RP103 approved for the treatment of nephropathic cystinosis. The company noted that the FDA has not asked for any additional studies …
Read more on Zacks.com